CUMBERLAND PHARMACEUTICALS INC

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) operates as a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceuticals. Based in Nashville, Tennessee, the company maintains its website at www.cumberlandpharma.com and serves patients primarily through hospital acute care, gastroenterology, and oncology markets.

The company's marketed product portfolio includes seven FDA-approved brands: Acetadote for acetaminophen poisoning treatment, Caldolor as an intravenous ibuprofen formulation for pain and fever management, Kristalose as a prescription laxative for constipation, Sancuso as a transdermal patch for chemotherapy-induced nausea and vomiting prevention, Vaprisol for hyponatremia treatment, Vibativ as an injectable antibiotic for serious bacterial infections, and Talicia as a combination therapy for Helicobacter pylori infection. The company distributes these products through dedicated hospital, field, and oncology sales divisions comprising approximately 60 sales professionals.

Cumberland's commercial infrastructure targets concentrated prescriber bases in its core therapeutic areas, allowing effective market penetration with relatively small, specialized sales forces. The company maintains relationships with three primary wholesale pharmaceutical distributors representing 27%, 25%, and 22% of consolidated gross revenues respectively. International expansion occurs through a network of established partners responsible for regulatory approvals, marketing, and distribution in their respective territories, with products marketed in countries including Australia, South Korea, Russia, Saudi Arabia, Mexico, and China.

The company's pipeline includes ifetroban, a selective thromboxane-prostanoid receptor antagonist in Phase II clinical development for Duchenne muscular dystrophy-associated cardiomyopathy, systemic sclerosis, and idiopathic pulmonary fibrosis. Cumberland Emerging Technologies, a majority-owned subsidiary, partners with academic research institutions to identify and develop promising product candidates for potential future commercialization.

Cumberland's business model emphasizes acquiring under-promoted FDA-approved drugs and late-stage development candidates rather than pursuing early-stage development, thereby minimizing associated risks and timelines. The company maintains robust internal capabilities in clinical development, regulatory affairs, quality assurance, and medical information support. In 2025, Cumberland provided nearly five million patient doses of its brands while maintaining no product recalls and no clinical trials terminated for failure to practice good clinical standards.